Avelumab Doesn’t Improve Survival in Platinum-Refractory Ovarian Cancer
There was no improvement in progression-free or overall survival.
Gynecologic Cancers
Benefit of Niraparib Maintenance May Extend Beyond First Progression in Ovarian Cancer
There was an improvement in second progression-free survival, but not overall survival, with niraparib.
Rucaparib Bests Standard of Care in BRCA-Mutated, Relapsed Ovarian Cancer
Rucaparib prolonged progression-free survival.
Atezolizumab Does Not Prolong Progression-Free Survival in Newly Diagnosed, Advanced Ovarian Cancer
There was no benefit with atezolizumab, regardless of PD-L1 status.
Public Interest in Cancer Screenings Decreased Early During the COVID-19 Pandemic
Researchers observed a “sharp” decline in public interest.
HER2-Targeted Therapies Demonstrate Activity in a Range of Solid Tumor Types
Efficacy differed by cancer type and KRAS status.
Most Women in Their Mid-60s May Need to Continue Cervical Cancer Screening
A minority of women met criteria to exit cervical cancer screening.
Rising Incidence of Endometrial Cancer Linked to Obesity in Younger Women
Data showed increases in endometrial cancer and obesity in women younger than 40.
The Challenge of Tumor Hypoxia-Associated Radioresistance in Cervical Cancer
This review discusses a consensus study on optimal management of tumor hypoxia in patients undergoing radiotherapy for cervical cancer.
Secondary Cytoreduction Improves Progression-Free Survival in Platinum-Sensitive, Relapsed Ovarian Cancer
The median progression-free survival was nearly 6 months longer in patients who underwent surgery.
- Loading...
Loading...
Next post in Ovarian Cancer
Loading... 
Loading...